Lung transplantation for coronavirus disease 2019 (COVID-19): The who, what, where, when, and why

Schaheen, Lara; Bremner, Ross M.; Walia, Rajat; Smith, Michael A.

doi:10.1016/j.jtcvs.2021.06.061

Cited by 14 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19-associated ARDS newly became an indication for LuTx [ 38 ]. However, the most critical aspects, such as the selection criteria of possible transplant candidates and the optimal timing of surgery, remain to be answered [ 38 , 39 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…Lung transplantation is the well-established ultimate treatment for a variety of end-stage chronic lung diseases worldwide, but its role in patients with ARDS remains controversial. Currently, lung transplantation is an acceptable indication in emergency settings, and might be considered in selected patients with refractory ARDS [ 38 , 39 , 40 , 41 ].…”

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

“…Lung injury and function can recover on ECMO within weeks to months [ 46 ]. However, some patients with ARDS still exhibit progression to end-stage lung disease, and thus, cannot be successfully separated from ECMO [ 38 ].…”

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

“…In this study, the 30-day mortality of the recipients was 0%, and 14 out of 19 patients were alive at the median follow-up of 134 (47–450) days [ 48 ]. Experts in the field suggested several factors that should be taken into consideration when assessing a patient with COVID-19-associated ARDS regarding potential candidacy for lung transplantation (based on initial experience) apart from the standard criteria for lung transplantation [ 38 , 39 , 49 , 50 ]. These factors are summarized in Table 1 .…”

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

See 3 more Smart Citations

How COVID-19 Affects Lung Transplantation: A Comprehensive Review

Vachtenheim

Novysedlák

Svorcova

et al. 2022

JCM

View full text Add to dashboard Cite

Lung transplant (LuTx) recipients are at a higher risk of developing serious illnesses from COVID-19, and thus, we have closely reviewed the consequences of the COVID-19 pandemic on lung transplantation. In most transplant centers, the overall LuTx activity significantly declined and led to a specific period of restricting lung transplantation to urgent cases. Moreover, several transplant centers reported difficulties due to the shortage of ICU capacities. The fear of donor-derived transmission generated extensive screening programs. Nevertheless, reasonable concerns about the unnecessary losses of viable organs were also raised. The overall donor shortage resulted in increased waiting-list mortality, and COVID-19-associated ARDS became an indication of lung transplantation. The impact of specific immunosuppressive agents on the severity of COVID-19 varied. Corticosteroid discontinuation was not found to be beneficial for LuTx patients. Tacrolimus concentrations were reported to increase during the SARS-CoV-2 infection, and in combination with remdesivir, tacrolimus may clinically impact renal functions. Monoclonal antibodies were shown to reduce the risk of hospitalization in SOT recipients. However, understanding the pharmacological interactions between the anti-COVID-19 drugs and the immunosuppressive drugs requires further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

Section: Lung Transplantation For Sars-cov-2 Infection—associated Ard...mentioning

confidence: 99%

See 2 more Smart Citations

How COVID-19 Affects Lung Transplantation: A Comprehensive Review

Vachtenheim

Novysedlák

Svorcova

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Finally, lung transplant has been performed for post-COVID-19 fibrosis [34], but there is significant difficulty in selecting the right patients at the best time, given that the natural course of the disease remains unknown [30]. A review of currently available literature suggests waiting for 8 weeks without clinical improvement [35]; patients are often bridged with extracorporeal membrane oxygenation during this time [36]. The national statistics for cardiothoracic transplant in the UK in 2020-2021 have not yet been published so it is not known how many patients have undergone this procedure.…”

Section: Treatmentmentioning

confidence: 99%

How COVID-19 interacts with interstitial lung disease

Myall

Martinovic

West

2022

Breathe

View full text Add to dashboard Cite

The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection.Educational aimsTo understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease.To explore the development of interstitial lung disease after COVID-19 infection.

show abstract